BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 517 filers reported holding BIO-TECHNE CORP in Q3 2023. The put-call ratio across all filers is 0.43 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,222,104 | -11.3% | 47,325 | +6.5% | 0.01% | -28.6% |
| Q2 2023 | $3,630,712 | +32.0% | 44,451 | +20.0% | 0.01% | +40.0% |
| Q1 2023 | $2,749,660 | -11.7% | 37,036 | -1.3% | 0.01% | -16.7% |
| Q4 2022 | $3,112,340 | +38.0% | 37,532 | +372.8% | 0.01% | +20.0% |
| Q3 2022 | $2,256,000 | -14.1% | 7,939 | +4.9% | 0.01% | -16.7% |
| Q2 2022 | $2,626,000 | -20.2% | 7,569 | -2.2% | 0.01% | 0.0% |
| Q1 2022 | $3,292,000 | -30.6% | 7,737 | -15.7% | 0.01% | -33.3% |
| Q4 2021 | $4,744,000 | +7.5% | 9,175 | +0.8% | 0.01% | 0.0% |
| Q3 2021 | $4,414,000 | +14.2% | 9,103 | +6.2% | 0.01% | +12.5% |
| Q2 2021 | $3,864,000 | +11.5% | 8,575 | -5.3% | 0.01% | 0.0% |
| Q1 2021 | $3,465,000 | +47.1% | 9,059 | +22.2% | 0.01% | +33.3% |
| Q4 2020 | $2,355,000 | +33.4% | 7,414 | +4.4% | 0.01% | +20.0% |
| Q3 2020 | $1,765,000 | +35.4% | 7,099 | +43.8% | 0.01% | +25.0% |
| Q2 2020 | $1,304,000 | +66.3% | 4,937 | +19.7% | 0.00% | +33.3% |
| Q1 2020 | $784,000 | – | 4,125 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ownership Capital B.V. | 972,263 | $308,742,000 | 4.35% |
| Sandhill Capital Partners LLC | 138,864 | $44,096,000 | 4.03% |
| STONE RUN CAPITAL, LLC | 27,350 | $8,685,000 | 3.45% |
| DF DENT & CO INC | 925,823 | $293,995,000 | 3.42% |
| Brown Capital Management | 1,498,233 | $475,764,000 | 3.29% |
| MAIRS & POWER INC | 848,081 | $269,308,000 | 2.99% |
| Summit Creek Advisors LLC | 64,179 | $20,380,000 | 2.62% |
| GENEVA CAPITAL MANAGEMENT LLC | 402,958 | $127,959,000 | 2.17% |
| Aristotle Atlantic Partners, LLC | 86,993 | $27,625,000 | 2.13% |
| CROWN ADVISORS MANAGEMENT, INC. | 8,000 | $2,540,000 | 1.82% |